Bioxytran, INC

Bioxytran, Inc. announced the completion of a $1.2 million private placement to fund working capital and advance development programs.

Bioxytran, Inc. modified its Convertible Preferred Stock conversion terms and awarded 6 million shares of Preferred Stock to CEO David Platt for commercial and capital funding efforts.

Bioxytran, Inc. announced positive Phase 1b/2a clinical study results for its broad-range antiviral drug, ProLectin-M, in mild to moderate COVID-19 patients.

Bioxytran, Inc. announced a commercial distribution agreement with Khoury Medical LTD for its A-SUQAR dietary supplement, marking a transition to commercial revenue.

Bioxytran, Inc. announced positive Phase 2 clinical trial results for ProLectin-M, demonstrating complete viral load elimination in 100% of treated patients by Day 7 compared to placebo.

Bioxytran, Inc. announced the termination of Mike Sheikh as an Officer, with Sheikh contesting the dismissal's reason and its impact on severance.

Bioxytran Inc. reported a net loss of $2.07 million for Q1 2026, an increase from the prior year, while facing substantial doubt about its ability to continue as a going concern due to insufficient capital.

Bioxytran's Q3 2025 report reveals significant liquidity challenges and a going concern warning, despite increased R&D and recent capital raise efforts.

Bioxytran, a clinical-stage pharmaceutical company, reported a significant accumulated deficit and negative working capital, raising substantial doubt about its ability to continue operations without immediate capital infusion.

Bioxytran, Inc. reports a widened net loss for the first quarter of 2025 as it continues to focus on research and development of its pharmaceutical products.

Bioxytran reports ongoing losses and raises concerns about its ability to continue as a going concern, despite advancements in its drug development pipeline and a recent subsidiary acquisition.

Bioxytran, a clinical-stage pharmaceutical company, announced its Q2 2024 results, highlighting ongoing efforts to secure funding for continued drug development and regulatory approvals.

Bioxytran, Inc. filed its annual report for the year ended December 31, 2025, detailing progress in its pharmaceutical development pipeline and financial status.

Bioxytran's Form 10-K reveals ongoing losses and dependence on future financing for its drug development programs, including BXT-25 and ProLectin-Rx, despite recent subsidiary acquisition and IND approvals.

Bioxytran Inc. has filed an amended annual report on Form 10-K, restating its financials for 2023 and 2022 due to errors in share valuation and reporting, while also disclosing a material weakness in internal controls.

Bioxytran, Inc. released its 2023 annual report, detailing financial results and advancements in its BXT-25 and ProLectin-Rx drug development programs.

BIOXYTRAN Director Alan M. Hoberman reported multiple acquisitions of preferred and common stock in the company, increasing his direct beneficial ownership.

BIOXYTRAN Director Radka Milanova acquired additional preferred shares in two separate transactions, increasing her beneficial ownership.

BIOXYTRAN Director Dale H. Conaway reported two separate acquisitions of preferred shares, increasing his beneficial ownership to 379,177 shares.

BIOXYTRAN Director Anders Utter acquired 38,588 preferred shares at $0.35, increasing his beneficial ownership to 372,580 shares.

BIOXYTRAN CEO David Platt amended his beneficial ownership, acquiring 11.4 million preferred shares as payment for the sale of NDPD to Bioxytran, while 14 million indirect shares were cancelled.

Bioxytran's Chief Commercial Officer and 10% owner, Michael Sheikh, acquired 6,614,720 preferred shares at $0.545 each as payment for the sale of NDPD Pharma to Bioxytran.

Bioxytran, Inc. files an amendment to its S-1 registration statement to include the opinion of legal counsel regarding the legality of issuing up to 18,000,000 shares of common stock.

Bioxytran is registering the resale of 18 million common shares by a selling stockholder, TRITON FUNDS LP, following a closing agreement for a maximum principal amount of $1.6 million.

Bioxytran, a clinical-stage pharmaceutical company, has filed a registration statement for the resale of 18 million shares of its common stock by a selling stockholder, Triton Funds LP.